Kintara Therapeutics (KTRA) has released an update.
Kintara Therapeutics, in collaboration with TuHura Biosciences, has reported promising outcomes from their Phase 1b trial, showcasing that their novel cancer vaccine, IFx-2.0, is both safe and effective in treating advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma resistant to standard checkpoint inhibitor therapies. A noteworthy 80% response rate was observed in ICI naïve patients with advanced MCC, demonstrating significant potential for IFx-2.0 to overcome immunotherapy resistance. These results were presented at the prestigious ASCO Annual Meeting, highlighting a major step forward in cancer immunotherapy.
For further insights into KTRA stock, check out TipRanks’ Stock Analysis page.
